The role of proteasome inhibitors in solid tumors

Annals of Medicine

Volumn 36, Issue 4, 2004, Pages 296-303

  Park, David J ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bortezomib; Proteasome; PS 341; Solid tumors; Velcade

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CARBOPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; PACLITAXEL; PROTEASOME INHIBITOR; TOPOTECAN;

ABDOMINAL PAIN; ANOREXIA; BLADDER CANCER; BLOOD TOXICITY; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ATRIUM FLUTTER; HEART INFARCTION; HUMAN; HYPERAMINOTRANSFERASEMIA; HYPERTENSION; ILEUS; KIDNEY CARCINOMA; LEUKOPENIA; LUNG CANCER; MELANOMA; METABOLIC DISORDER; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SARCOMA; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TRANSAMINITIS; VOMITING;

BORONIC ACIDS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYSTEINE ENDOPEPTIDASES; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 2942708234     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890410029031     Document Type: Review

References (44)

1. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-9.
2. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-85.
3. Conaway RC, Brower CS, Conaway JW. Emerging roles of ubiquitin in transcription regulation. Science 2002;296:1254-8.
4. Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res 2003;5:8-15.
5. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47.
6. Ciechanover A. The ubiquitin-proteasome pathway, on protein death and cell life. EMBO J 1998;17:7151-60.
7. Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998;77:448-55.
8. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503-33.
9. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13.
10. WAF/CIP1 expression. Biochem Biophys Res Com 1996;227:564-9.
11. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
12. Machiels BM, Henfling ME, Gerards WL, Broers JL, Bloemendal H, Ramaekers FC, et al. Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry 1997;28:243-52.
13. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56:2649-54.
14. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, Beijersbergen RL. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev 1996;10:2960-70.
15. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;274:782-4.
16. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996;274:787-9.
17. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996;274:784-7.
18. Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-5.
19. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999;13:382-7.
20. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new-discoveries and insights. Annu Rev Immunol 1996;14:649-83.
21. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-KB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000;14:399-402.
22. Tricot G. New insights into the role of microenvironment in multiple myeloma. Lancet 2000;355:248-50.
23. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
24. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.
25. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
26. Wang CY, Cusack JC, Jr, Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-7.
27. Cusack JC, Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-40.
28. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997;272:24159-64.
29. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110-22.
30. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-7.
31. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
32. Papandreou C, Daliani D, Millikan RE, Tu S, Pagliaro L, Adams J, et al. Phase I Study of Intravenous (I.V.) Proteasome Inhibitor PS-341 in Patients with Advanced Malignancies. In: American Society of Clinical Oncology, Abst 340; 2001:2001.
33. Erlichman C, Adjei AA, Thomas JP, Wilding G, Reid JM, Sloan JA, et al. A Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Advanced Cancer. In: American Society of Clinical Oncology, Abst 337; 2001; San Francisco, CA2001.
34. Supko JG, Eder JP, Lynch TJ, Belonogovna N, Guerciolini R, Cusack JC, et al. Pharmacokinetics of irinotecan and the proteasome inhibitor bortezomib in adult patients with solid malignancies. In: American Society of Clinical Oncology, Abst 544; 2003; Chicago, IL2003.
35. Albanell J, Baselga J, Guix M, Twelves CT, Glasspool R, Awada A, et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. In: American Society of Clinical Oncology, Abst 63; 2003; Chicago, IL2003.
36. Appleman LJ, Ryan DP, Clark JW, Eder JP, Fishman M, Cusack JC, et al. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. In: American Society of Clinical Oncology, Abst 839; 2003; Chicago, IL2003.
37. Roth BJ, Dreicer R, Berg W, Myers M, Boral A, Esseltine D, et al. Phase I/II trial of bortezomib (PS-341) plus docetaxel in patients with advanced androgen-independent prostate cancer. In: American Society of Clinical Oncology, Abst 1705; 2003; Chicago, IL2003.
38. Ryan DP, O'Neil B, Lima CR, Eder JP, Lynch TL, Cusack JC, et al. Phase I dose-escalation study of the proteasome inhibitor, bortezomib, plus irinotecan in patients with advanced solid tumors. In: American Society of Clinical Oncology, Abst 915; 2003; Chicago, IL2003.
39. Lebowitz PF, Harkins C, Conley B, Headlee D, Camphausen K, Guis D, et al. Concomitant therapy with proteasome inhibitor, bortezomib, and radiation in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). In: American Society of Clinical Oncology, Abst 2010; 2003; Chicago, IL2003.
40. Dees EC, O'Neil B, Humes E, Hall M, Carey L, Collichio F, et al. Phase I clinical trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. In: American Society of Clinical Oncology, Abst 868; 2003; Chicago, IL2003.
41. Thomas JP, Arzoomanian R, Alberti D, Geiger P, Marnocha R, Tutsch K, et al. A phase I and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin. In: American Society of Clinical Oncology, Abst 368; 2002; Orlando, FL2002.
42. Iqbal S, Lenz H-J, Groshen S, Wei Y, Gandara DR, Lara PN, et al. Phase I study of PS-341 in combination with 5-FU/LV in solid tumors. In: American Society of Clinical Oncology, Abst 370; 2002; Orlando, FL2002.
43. Maki R, Kraft A, Demetri GD, Siegel E, Hirst C, Connors S, et al. A phase II multicenter study of proteasome inhibitor PS-341 (LDP-341, bortezomib) for untreated recurrent or metastatic soft tissue sarcoma (STS); CTEP study 1757. In: American Society of Clinical Oncology, Abst 3291; 2003; Chicago, IL2003.
44. Shah MH, Martin E, Ellison C, Kraut E, Kindler H, Young D, et al. A phase II study of proteasome inhibitor PS-341 in metastatic neuroendocrine tumors. In: American Society of Clinical Oncology, Abst 111; 2002; Orlando, FL2002.